How Biotechs Survive the Valley of Death

<p>Follow us on <a href="https://www.linkedin.com/company/biotechnology-innovation-organization/posts/?feedView=all" target="_blank">LinkedIn</a>, <a href="https://twitter.com/IAmBiotech" target="_blank">X</a>, <a href="https://www.facebook.com/IAmBiotech/" target="_blank">Facebook</a> and <a href="https://www.instagram.com/iambiotech/" target="_blank">Instagram</a>. </p><p>Visit us at <a href="https://www.bio.org/" target="_blank">https://www.bio.org/</a></p><p>For biotech companies, the valley of death describes the difficult path from initial discovery to FDA approval and commercialization. It's a treacherous journey—one that even promising innovations often don't complete. Adequate funding, regulatory hurdles and the immense complexity of the biotech landscape are among the never-ending challenges faced by early stage biotechs. In this episode we talk with two biotech executives about what it’s like to struggle and survive in this rough-and-tumble industry. </p>